BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s share price traded down 3.1% on Friday . The company traded as low as $2.48 and last traded at $2.48, with a volume of 53,296 shares. The stock had previously closed at $2.56.

Separately, Maxim Group reissued a “buy” rating and issued a $5.00 price target on shares of BrainStorm Cell Therapeutics in a report on Saturday, June 4th.

The company’s market capitalization is $46.26 million. The firm has a 50-day moving average price of $2.54 and a 200-day moving average price of $2.42.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.13. Equities analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.34) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.